Jones Trading Reaffirms “Hold” Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “hold” rating reaffirmed by investment analysts at Jones Trading in a research report issued on Tuesday,Benzinga reports.

A number of other equities analysts have also weighed in on the stock. HC Wainwright decreased their price objective on shares of Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating for the company in a report on Monday. Citizens Jmp decreased their price target on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a research note on Friday. Oppenheimer set a $27.00 price objective on Intellia Therapeutics in a research report on Friday. Truist Financial reissued a “buy” rating and issued a $14.00 target price (down previously from $25.00) on shares of Intellia Therapeutics in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Hold” and a consensus target price of $18.25.

Intellia Therapeutics Stock Up 4.8%

Shares of NASDAQ:NTLA traded up $0.47 on Tuesday, hitting $10.20. 4,908,653 shares of the company traded hands, compared to its average volume of 5,151,128. The stock has a 50 day simple moving average of $17.16 and a 200-day simple moving average of $12.54. The company has a market cap of $1.09 billion, a PE ratio of -2.39 and a beta of 2.45. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.34) EPS. As a group, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity

In other news, CAO Michael P. Dube sold 1,871 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were bought at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the transaction, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Blue Bell Private Wealth Management LLC purchased a new position in shares of Intellia Therapeutics during the 3rd quarter valued at $30,000. Headlands Technologies LLC bought a new stake in Intellia Therapeutics during the second quarter valued at about $26,000. Federated Hermes Inc. raised its holdings in Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after acquiring an additional 927 shares during the period. Whipplewood Advisors LLC lifted its position in shares of Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after acquiring an additional 3,447 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after acquiring an additional 1,655 shares during the period. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.